CAJ | 학술논문

目的：比较自研注射用紫杉醇(清蛋白结合型,PAB)与原研注射用紫杉醇(清蛋白结合型,Abraxane)的体内抗肿瘤作用。方法建立小鼠H22、Lewis和RM-1肿瘤模型,荷瘤小鼠分别静脉注射13.4,20.0,30.0,45.0 mg·kg-1剂量的PAB和20.0和(或)30.0 mg·kg-1剂量的Abraxane,比较给药后PAB组与Abraxane组的抗肿瘤作用。结果PAB 13.4,20.0,30.0,45.0 mg · kg-1剂量组均能显著抑制 H22肿瘤生长, PAB 20.0 mg · kg-1剂量组与等剂量的Abraxane组比较对H22肿瘤地抑制作用差异无统计学意义。 PAB 20.0,30.0,45.0 mg·kg-1剂量组可剂量依赖性地抑制Lewis和RM-1肿瘤生长,PAB和Abraxane对C57雌性荷瘤小鼠的最大无毒剂量均为20.0 mg·kg-1。 PAB各剂量组与等剂量的Abraxane组比较,对RM-1和Lewis肿瘤生长的抑制作用和对荷瘤小鼠的毒性均差异无统计学意义。结论相同给药剂量下,PAB的体内抗肿瘤作用和毒性与原研品Abraxane相同。
목적：비교자연주사용자삼순(청단백결합형,PAB)여원연주사용자삼순(청단백결합형,Abraxane)적체내항종류작용。방법건립소서H22、Lewis화RM-1종류모형,하류소서분별정맥주사13.4,20.0,30.0,45.0 mg·kg-1제량적PAB화20.0화(혹)30.0 mg·kg-1제량적Abraxane,비교급약후PAB조여Abraxane조적항종류작용。결과PAB 13.4,20.0,30.0,45.0 mg · kg-1제량조균능현저억제 H22종류생장, PAB 20.0 mg · kg-1제량조여등제량적Abraxane조비교대H22종류지억제작용차이무통계학의의。 PAB 20.0,30.0,45.0 mg·kg-1제량조가제량의뢰성지억제Lewis화RM-1종류생장,PAB화Abraxane대C57자성하류소서적최대무독제량균위20.0 mg·kg-1。 PAB각제량조여등제량적Abraxane조비교,대RM-1화Lewis종류생장적억제작용화대하류소서적독성균차이무통계학의의。결론상동급약제량하,PAB적체내항종류작용화독성여원연품Abraxane상동。
Objective To compare the antitumor effect of self-developed albumin bound paclitaxel for injection ( PAB) and commercial albumin-bound paclitaxel for injection ( Abraxane ) . Methods The antineoplastic effects of PAB and Abraxane were evaluated in H22, Lewis and RM-1 allograft tumor mouse models after repeated intravenous injection (13. 4, 20. 0, 30. 0 and 45. 0 mg·kg-1 PAB and 20. 0 and/or 30. 0 mg·kg-1 Abraxane, respectively). Results PAB significantly inhibited H22 tumor growth at from the doses of 13. 4, 20. 0, 30. 0, and 45. 0 mg·kg-1,and the antitumor effect of PAB at 20. 0 mg·kg-1 was not significantly different from Abraxane at 20. 0 mg·kg-1 . PAB dose-dependently inhibited Lewis and RM-1 tumor growth at the doses of 20. 0, 30. 0, and 45. 0 mg·kg-1 . The no observed adverse effect level of PAB and Abraxane was 20. 0 mg· kg-1 in Lewis and RM-1 bearing C57 female mice. The antitumor effect and toxicity was not significantly different between PAB and Abraxane at equivalent doses. Conclusion At the same dose level, the antitumor activity and toxicity of PAB was equivalent to those of Abraxane.